ABL1 and pulmonary arterial hypertension: In addition, clinical studies suggest that the Abl inhibitor imatinib is effective to lessen the clinical symptoms of patients with pulmonary arterial hypertension [65, 66], a disease that is also involved in abnormal smooth muscle cell contraction and proliferation.